“There are several other discussions that we have been having with private equity investors who are interested in making an investment in Biocon Biologics and that will help us bring down the $1.2 billion debt … help us reduce the interest component that we see in the P&L,” Shreehas Tambe, chief executive officer and managing director of Biocon Biologics, said in an interview.
How a $900 million bet on SpaceX turned 100x into $94 billion for Alphabet
Alphabet’s initial $900 million SpaceX investment is now worth approximately $94 billion. This significant return makes Alphabet the largest institutional shareholder in the rocket company.
August 14, 2026